Valeant Pharmaceuticals, Vuzix, Tiffany News Today

Valeant Pharmaceuticals Intl Inc, Vuzix Corporation, and Tiffany are in the news today

Mar 17, 2017 at 9:30 AM
facebook twitter linkedin

Stock futures are trading near fair value ahead of today's G-20 summit, which will include U.S. Treasury Secretary Steven Mnuchin. Among stocks in focus are pharmaceutical firm Valeant Pharmaceuticals Intl Inc (NYSE:VRX), wearable tech name Vuzix Corporation (NASDAQ:VUZI), and luxury retailer Tiffany stock, Here's a quick roundup of the headlines moving shares of VRX, VUZI, and TIF stock.

ValueAct Gives Valeant Pharmaceuticals a Post-Ackman Nod

VRX stock is trading up 4.2% ahead of the bell, after closing last night at $11.20. Boosting the shares is news that ValueAct increased its stake in Valeant Pharmaceuticals Intl Inc to 5.2%, calling the shares "undervalued." This comes just days after Bill Ackman announced he threw in the towel on his losing VRX bet. Valeant shares could definitely use some upside, considering they've shed nearly 23% year-to-date -- and roughly 67% year-over-year. Short sellers have certainly been on the winning side of VRX, too, with more than 11% of the stock's float sold short.

Earnings Have Vuzix Stock at Risk of Erasing 2017 Gains

Shares of VUZI are down 11.9% in electronic trading, after the company's fourth-quarter revenue came up far short of the consensus estimate. Today's projected price move could send the shares back into the red on a year-to-date basis. A continued struggle could prompt a round of bearish brokerage notes from the upbeat analyst bunch. Three analysts currently cover Vuzix Corporation, each of which has issued a "buy" rating toward the stock. Plus, the average 12-month price target of $10.50 stands at a 45.8% premium to last night's close at $7.20 and territory not charted in six years.

TIF Stock Set to Pop After Earnings Win

TIF stock is set to climb 3.7% out of the gate to a fresh annual high, after the retailer turned in better-than-expected earnings and an encouraging forecast. Tiffany shares have already had an impressive run in 2017, up 16.2%, based on last night's settlement at $89.98. TIF options traders have been buying to open calls over puts at a faster-than-usual clip ahead of earnings, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), TIF's 10-day call/put volume ratio of 1.20 ranks in the elevated 63rd annual percentile.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!